What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Disease
Francesco Blasi mostly deals with Urokinase receptor, Molecular biology, Receptor, Intensive care medicine and Internal medicine.
His research in Urokinase receptor intersects with topics in Cell migration, Cell adhesion and Cell biology.
His Molecular biology research also works with subjects such as
- Epitope, which have a strong connection to Vitronectin,
- Signal transduction, which have a strong connection to Integrin.
Francesco Blasi interconnects Cell and Cellular differentiation in the investigation of issues within Receptor.
His work carried out in the field of Intensive care medicine brings together such families of science as Community-acquired pneumonia, Pneumonia, Bronchiectasis, Respiratory infection and Disease management.
His research integrates issues of Gastroenterology, Placebo and Multiple drug resistance in his study of Internal medicine.
His most cited work include:
- Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. (570 citations)
- Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors (560 citations)
- Guidelines for the management of adult lower respiratory tract infections ‐ Full version (531 citations)
What are the main themes of his work throughout his whole career to date?
Francesco Blasi mainly focuses on Internal medicine, Intensive care medicine, Pneumonia, COPD and Immunology.
His biological study spans a wide range of topics, including Gastroenterology, Sputum and Antibiotics.
His Intensive care medicine study combines topics in areas such as Disease and MEDLINE.
Francesco Blasi is interested in Community-acquired pneumonia, which is a branch of Pneumonia.
His COPD research incorporates themes from Exacerbation and Cohort.
His research on Immunology frequently links to adjacent areas such as Mycoplasma pneumoniae.
He most often published in these fields:
- Internal medicine (37.30%)
- Intensive care medicine (19.89%)
- Pneumonia (17.22%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (37.30%)
- Bronchiectasis (11.51%)
- Coronavirus disease 2019 (4.85%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Bronchiectasis, Coronavirus disease 2019, Asthma and Cystic fibrosis.
He has researched Internal medicine in several fields, including Gastroenterology, Antibiotics and MEDLINE.
His Bronchiectasis study combines topics from a wide range of disciplines, such as Microbiome, Exacerbation, Immunology and Sputum.
His Coronavirus disease 2019 research is multidisciplinary, incorporating perspectives in Intensive care medicine, Pneumonia and 2019-20 coronavirus outbreak.
Francesco Blasi combines subjects such as Anesthesia, Mechanical ventilation, Pandemic and Etiology with his study of Pneumonia.
His Asthma research includes elements of COPD and Epidemiology.
Between 2018 and 2021, his most popular works were:
- Complement activation in patients with COVID-19: A novel therapeutic target. (84 citations)
- Electronic cigarettes: a task force report from the European Respiratory Society (73 citations)
- Characterization of Myocardial Injury in Patients With COVID-19. (50 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Disease
Francesco Blasi spends much of his time researching Internal medicine, Coronavirus disease 2019, Bronchiectasis, Pneumonia and Asthma.
His study focuses on the intersection of Internal medicine and fields such as MEDLINE with connections in the field of Intensive care medicine and Severe asthma.
His Bronchiectasis study incorporates themes from Disease progression, Exacerbation, Immunology, Nasal polyps and Sputum.
Francesco Blasi studies Pneumonia, namely Community-acquired pneumonia.
His research in Community-acquired pneumonia intersects with topics in Cross-sectional study and Etiology.
His research integrates issues of Omalizumab, Epidemiology, Health care and Cohort in his study of Asthma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
